

Today's Information

Provided by: Senhwa Biosciences, Inc.

SEQ_NO	1	Date of announcement	2024/01/05	Time of announcement	14:00:43
Subject	Due to strategy adjustment, the Company decides to early terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19.				
Date of events	2024/01/05	To which item it meets	paragraph 53		

Statement	1.Date of occurrence of the event:2024/01/05				
	2.Company name:Senhwa Biosciences Inc.				
	3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office				
	4.Reciprocal shareholding ratios:Not applicable				
	5.Cause of occurrence:				
	(1)The Company previously has obtained IND application approvals from the US FDA and Taiwan FDA with respect to the clinical trials of Silmitasertib (CX-4945) for treating community-acquired pneumonia (CAP) patients associated with viral infections (SARS-CoV-2 and Influenza). However, in consideration of strategy adjustment, the Company has decided to officially notify the National Cheng Kung University Hospital of early termination of the Phase II clinical trial of Silmitasertib (CX-4945) for the treatment of hospitalized patients with COVID-19.				
	(2)For the information about the Phase II clinical trial ofSilmitasertib (CX-4945) for the treatment of community-acquired pneumonia (CAP) patients caused by pan-viral infections, please refer to the company's major announcement on December 25, 2023.				
	(3)A single clinical trial result does not reflect the success or failure of new drug development and launch in the future. Investors should make prudent judgments and investments.				
	6.Countermeasures:With the discontinuation of this Phase II clinical trial of Silmitasertib (CX-4945) for the treatment of hospitalized patients with COVID-19, the Company is able to allocate resources to other clinical plans with more cost effective structures.				
	7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None. The time-phase for drug development is long, the investment is huge, and there is no guarantee of success, which may put investment at risk. Investors should make prudent judgments and investments.				